Novavax

Historical price data

Novavax is a mission-driven biotech focused on discovering, developing, and commercializing innovative protein-based vaccines to address serious infectious diseases. Its core achievement is the successful global commercialization of Nuvaxovid®, a COVID-19 vaccine, validating its integrated technology platform of recombinant nanoparticle antigens and the Matrix-M adjuvant. The company's strategy centers on advancing a high-value pipeline in influenza and other infectious diseases while pursuing strategic partnerships and exploring new applications for its adjuvant technology in areas like oncology to drive long-term growth.

An integrated platform combining recombinant protein-based nanoparticles that mimic native viral structures with the Matrix-M® adjuvant, a saponin-based immunostimulant, to generate potent and broad immune responses.

Novavax competes against mRNA giants (Pfizer, Moderna) in COVID-19 and established flu vaccine leaders (Sanofi, GSK, Seqirus). Its differentiation lies in its protein-based platform's tolerability and thermostability profile, and the proven performance of its Matrix-M adjuvant, which also competes with adjuvants from GSK and Dynavax.